Crossmark

Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. Wolf

Crossref DOI link: https://doi.org/10.1007/s00198-019-05025-3

Published Online: 2019-05-29

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Biver, E. https://orcid.org/0000-0001-6174-1951
Calmy, A.

Meier, C.
License Information

Text and Data Mining valid from 2019-05-29

Version of Record valid from 2019-05-29
More Information

Article History

Received: 17 May 2019

Accepted: 17 May 2019

First Online: 29 May 2019

Compliance with ethical standards

:

: Alexandra Calmy has received travel grants from Gilead and unrestricted educational grants from Gilead, ViiV, MSD, and AbbVie. Emmanuel Biver and Christian Meier declare that they have no conflict of interest.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below